From Territories to Networks: The 2026 State of HCP Targeting

A Data-Backed Report for Pharma & MedTech Commercial Teams

For three decades, healthcare commercial targeting has rested on three assumptions: that the individual physician is the decision-maker, that physical proximity predicts rep efficiency, and that historical volume predicts future volume.

Healthcare consolidation has quietly invalidated all three. Today, more than 80% of U.S. hospitals belong to an integrated delivery network (IDN), and rep access to physicians has fallen from 60% in 2022 to 45% in 2024.

Yet most field models are still drawn on a ZIP-code map.

This report explains why geography-based targeting is breaking down — and how leading pharma and MedTech teams are replacing it with a network-based approach built on affiliation, influence, and code-level claims data.

📥 Download the White Paper

Includes:

• Why the ZIP-code targeting model is failing
• The four layers of how HCP decisions actually get made
• How pharma and MedTech targeting differ — and why one playbook won’t work for both
• A targeting maturity self-assessment
• 5 actionable tips you can apply this quarter

What You’ll Learn Inside the Report

Modern commercial success no longer depends on covering a territory. It depends on understanding how health systems, committees, and referral networks actually drive prescribing and purchasing.

Inside the report you’ll learn:

✅ Why the three assumptions behind geographic targeting no longer hold

✅ How consolidation and the HCP access crisis changed the game

✅ The four-layer model of HCP decision-making — institutional, clinical, influence, and access

✅ How pharma (formulary, P&T, prescriptions) and MedTech (VAC, surgeons, procedures) differ

✅ How to build influence maps and referral intelligence instead of decile lists

✅ The data infrastructure required to target by network, not geography

✅ A maturity model to locate your team — and 5 tips to start now

Who This Report Is For

This report is designed for:

• Pharma and MedTech commercial leaders
• Sales operations and field-force strategy teams
• Medical affairs and KOL engagement teams
• Marketing and omnichannel teams
• Market access and key-account teams

If your team designs territories, builds target lists, or measures field performance, this report gives you a clear framework for targeting in a consolidated healthcare market.

Why HCP Targeting Is Breaking Down

Many commercial teams underestimate how much healthcare consolidation has changed who actually makes decisions.

The decision a rep is trying to influence is increasingly made upstream — by people the rep never meets:

• Pharmacy & Therapeutics committees and formularies
• Value Analysis Committees and GPO/IDN supply-chain contracting
• Order sets, clinical pathways, and EHR defaults
• System specialty leads and referral networks

On top of that, access is scarce and goodwill is thin: pharma averages a −10% Net Promoter Score with physicians, and half of still-accessible HCPs now meet with three or fewer companies. Understanding these dynamics early dramatically improves field efficiency and adoption.

What’s Inside the Report

The report provides a structured framework for modern HCP targeting, including:

1. The Model That Worked — and Its Assumptions

Why geographic targeting was correctly designed for a market structure that no longer exists.

2. Consolidation & the Access Crisis

How IDNs, declining rep access, and negative sentiment broke the old model.

3. How HCP Decisions Actually Get Made

The four layers of influence — and how they differ for pharma vs MedTech.

4. The Cost of the Mismatch

Fragmented accounts, misleading volume data, and effort spread across the wrong targets.

5. The Network-Based Alternative

Affiliations as a primary filter, influence maps over decile lists, and referral-based sequencing.

6. The Data Infrastructure It Requires

Code-level claims (CPT, HCPCS, ICD-10), affiliation and referral mapping, cohort analysis, and CRM integration.

Bonus: 5 Actionable Tips to Start Now

The report closes with five practical moves you can begin this quarter, including how to:

• Re-anchor targeting on affiliation before geography
• Replace decile lists with influence maps
• Match your data signal to your modality (pharma vs MedTech)
• Coordinate coverage across territory lines
• Measure decisions influenced, not dials made

📥 Download the Full Report

Ready to see your market as a network?

Learn why geography-based targeting is failing — and how to find, segment, and engage the HCPs who actually drive prescribing and purchasing in a consolidated healthcare market.